Updated on 1 October 2012
Curadev is also in the process of patenting three distinct series of molecules
Singapore: New Delhi-based Curadev Pharma has successfully advanced its oncology program to the next stage with its clinical development partner, Endo Pharmaceuticals, triggering a milestone payment.
Mr Manish Tandon, chief financial officer at Curadev, said, "Endo partnered with us when we had a good idea but no intellectual property. This collaboration is a validation of a new business paradigm in asset creation partnerships. We are in the process of patenting three distinct series of molecules which are potent, bioavailable and show a pharmacodynamic effect in animals."
He added, "Curadev has quickly established a non-bureaucratic, decision-focused culture that respects individuals and this is critical for the success of an organization that depends on creativity."
Dr Arjun Surya, chief scientific officer at Curadev, said, "This is an important milestone for our organization and it is very satisfying to see the progress of a program that has been conceived by our scientists. We have worked on a completely new program and have met and surpassed the efficacy and bioavailability criteria established jointly before starting the research program. This program is also a validation of our platform process that we use to find novel composition of matter since our each of our lead series have directly evolved from this process."
Dr Sandeep Gupta, senior vice president, discovery and early development at Endo, stated, "We are extremely pleased with the creativity, productivity and collaborative spirit of the scientific team at Curadev. In a short span of less than one year, they have not only designed potent, novel molecules but also demonstrated activity of these molecules in animal models. I congratulate Curadev leadership and scientific team on achievement of this important milestone."